search

Active clinical trials for "Squamous Cell Carcinoma of Head and Neck"

Results 781-790 of 1255

Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Recurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the Hypopharynx32 more

This phase II trial studies how well lapatinib ditosylate works in treating patients with metastatic or recurrent head and neck cancer. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Completed27 enrollment criteria

Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Metastatic Squamous Neck Cancer With Occult Primary14 more

Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. This phase II trial is studying how well lapatinib works in treating patients with recurrent and/or metastatic head and neck cancer.

Completed42 enrollment criteria

Zalutumumab in Head and Neck Cancer

Head and Neck Neoplasms

The purpose of this trial is to determine the safety of zalutumumab as a treatment for head and neck cancer.

Completed13 enrollment criteria

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult Primary20 more

This phase II trial is studying how well SB-715992 works in treating patients with recurrent or metastatic head and neck cancer. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die.

Completed43 enrollment criteria

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Male Breast CancerRecurrent Adenoid Cystic Carcinoma of the Oral Cavity75 more

This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as alvespimycin hydrochloride, work in different ways to stop tumor cells from dividing so they stop growing or die.

Completed78 enrollment criteria

Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head...

Recurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the Hypopharynx20 more

Phase I/II trial to study the effectiveness of combining erlotinib with docetaxel in treating patients who have locally advanced, recurrent, or metastatic head and neck cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more tumor cells.

Completed49 enrollment criteria

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer...

Recurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the Larynx11 more

This randomized phase I/II trial is to see if combining erlotinib with bevacizumab works better in treating patients who have recurrent or metastatic head and neck cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes needed for tumor cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining erlotinib with bevacizumab may kill more tumor cells.

Completed66 enrollment criteria

Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced...

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Adenoid Cystic Carcinoma of the Oral Cavity52 more

Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining monoclonal antibody therapy with chemotherapy and radiation therapy may be an effective treatment for head and neck cancer. This phase I trial is to see if combining bevacizumab, fluorouracil, and hydroxyurea with radiation therapy works in treating patients who have advanced head and neck cancer

Completed50 enrollment criteria

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu...

Advanced Adult Primary Liver CancerAnaplastic Thyroid Cancer125 more

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy

Completed26 enrollment criteria

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced...

HER2 Positive Gastric CancerColorectal Cancer9 more

This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: Regimen A: FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies. Regimen B: FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors. Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.

Completed20 enrollment criteria
1...787980...126

Need Help? Contact our team!


We'll reach out to this number within 24 hrs